032491] 12 . Hui EP, Taylor GS, Jia H, Ma BB, Chan SL, Ho
032491] 12 . Hui EP, Taylor GS, Jia H, Ma BB, Chan SL, Ho R, Wong WL, Wilson S, Johnson BF, Edwards C, et al. Phase I trial of recombinant modified vaccinia Ankara encoding Epstein-Barr viral tumor antigens in nasopharyngeal carcinoma sufferers. Cancer Res. 2013; 73:1676688. A completely created trial whose hypothesis is that enhanced recognition of tumor cells via their expression of EBNA antigens EBNA-1 and LMP-2 will likely be therapeutic. Safety, immunogenicity, as well as a dose-response effect were demonstrated. [PubMed: 23348421] 13. Balfour HH Jr. Epstein-Barr virus vaccine for the prevention of infectious mononucleosis–and what else J Infect Dis. 2007; 196:1724726. [PubMed: 18190249]NIH-PA Author Manuscript NIH-PA Author Manuscript NIH-PA Author ManuscriptCurr Opin Virol. Author manuscript; accessible in PMC 2015 June 01.BalfourPage14. Nemerow GR, Mold C, Schwend VK, Tollefson V, Cooper NR. Identification of gp350 because the viral glycoprotein mediating attachment of Epstein-Barr virus (EBV) to the EBV/C3d receptor of B cells: sequence homology of gp350 and C3 complement fragment C3d. J Virol. 1987; 61:14161420. [PubMed: 3033269] 15. Moss DJ, Pope JH. Assay of the infectivity of Epstein-Barr virus by transformation of human leucocytes in vitro. J Gen Virol. 1972; 17:23336. [PubMed: 4344316] 16. Sashihara J, Burbelo PD, Savoldo B, Pierson TC, Cohen JI. Human antibody titers to Epstein-Barr Virus (EBV) gp350 correlate with neutralization of infectivity much better than antibody titers to EBV gp42 making use of a fast flow cytometry-based EBV neutralization assay. Virology. 2009; 391:24956. [PubMed: 19584018] 17. Moghaddam A, Rosenzweig M, Lee-Parritz D, Annis B, Johnson RP, Wang F. An animal model for acute and persistent Epstein-Barr virus infection. Science. 1997; 276:2030033. [PubMed: 9197263] 18 Sashihara J, Hoshino Y, Bowman JJ, Krogmann T, Burbelo PD, Coffield VM, Kamrud K, Cohen JI. Soluble rhesus lymphocryptovirus gp350 protects against infection and reduces viral loads in animals that turn out to be infected with virus immediately after challenge. PLoS Pathog. 2011; 7:e1002308. An important study in which rhesus macques have been protected from an EBV challenge infection soon after receiving gp350 vaccine. [PubMed: 22028652] 19 Balfour HH Jr, Odumade OA, Schmeling DO, Mullan BD, Ed JA, Knight JA, Vezina HE, Thomas W, Hogquist KA. Behavioral, virologic, and immunologic elements connected with acquisition and severity of main Epstein-Barr virus infection in university students. J Infect Dis. 2013; 207:808. A prospective study demonstrating the considerable illness burden of main EBV infection in EBV-na e college freshmen. Such students are perfect subjects for a vaccine study whose key endpoint is protection from infectious mononucleosis. [PubMed: 23100562] 20. Balfour HH Jr, GCN5/PCAF Inhibitor review Holman CJ, Hokanson KM, Lelonek MM, Giesbrecht JE, White DR, Schmeling DO, Webb C, Cavert W, Wang DH, et al. A prospective clinical study of Epstein-Barr virus and host interactions through acute infectious mononucleosis. J Infect Dis. 2005; 192:JAK1 Inhibitor custom synthesis 1505512. [PubMed: 16206064] 21. Holman CJ, Karger AB, Mullan BD, Brundage RC, Balfour HH Jr. Quantitative Epstein-Barr virus shedding and its correlation together with the danger of post-transplant lymphoproliferative disorder. Clin Transplant. 2012; 26:74147. [PubMed: 22385033] 22. Kanakry JA, Li H, Gellert LL, Lemas MV, Hsieh WS, Hong F, Tan KL, Gascoyne RD, Gordon LI, Fisher RI, et al. Plasma Epstein-Barr virus DNA predicts outcome in advanced Hodgkin lymphoma: corre.
